A Novel Room Temperature Stable Circular RNA Platform for Production of Proteins & Peptides to Treat Different DiseasesA Novel Room Temperature Stable Circular RNA Platform for Production of Proteins & Peptides to Treat Different Diseases
- Showcasing the development of a circular RNA platform that is room temperature stable, durable for a long period of time in vivo after administration and results in very high protein production starting shortly after administration
- Administrating circular RNA using microneedle patches resulting in preferential targeting of the circular RNA to the cells that produce protein in vivo to treat cancers, autoimmune, fibrosis and other diseases and will be used on human patients as part of Circurna’s first Phase I clinical trial in early 2027
- Developing a novel and industry leading purification manufacturing protocol that results in high circularization, high yield, high purity at a low cost